Download our sample post-conference report now or receive the full version by contacting us.
The 2022 ASCO Annual Meeting has concluded and in its wake lies 117 ADC-related abstracts that have been carefully screened and added to the Beacon database. Of these 117 abstracts, 115 (98%) presented studies that investigate ADCs in the clinic for the first approval, and the remaining two were investigated in the preclinical setting.
Almost half of the abstracts, 47% (55/117), focus on approved ADC drugs with KADCYLA® and ENHERTU® being the most discussed approved ADCs at ASCO 2022.
For more insight please download the sample, contact us, or request a demo.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements